ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

With acquisition, Fujifilm takes medical ops center stage

Buying Wako Pure Chemical chance to turn profit on regenerative medicine

Inside Fujifilm's regenerative medicine laboratory.

TOKYO -- Fujifilm Holdings' pending acquisition of Wako Pure Chemical Industries marks a big step forward for the company's regenerative medicine business, seen helping drive growth as traditional mainstay operations sag.

The Japanese imaging company's board on Thursday approved a plan to have core unit Fujifilm acquire the research reagents maker from Takeda Pharmaceutical by April 2017 via a 154.7 billion yen ($1.31 billion) tender offer starting in late February. Wako will also repurchase more than 30% of its own shares at the time of the acquisition at a cost of 97 billion yen.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more